Gastroparesis treatment options metoclopramide and prucalopride: analysis of the FDA Adverse Event Reporting System (FAERS) database.

BACKGROUND

We aimed to examine the common adverse drug reactions (ADRs) of metoclopramide, FDA-approved for treating many gastrointestinal conditions including gastroparesis, and prucalopride, FDA-approved for treating chronic idiopathic constipation but used off-label for other gastrointestinal conditions including gastroparesis.

RESEARCH DESIGN AND METHODS

The FDA Adverse Event Reporting System (FAERS) was analyzed from January 2013 to December 2023. ADR reports regarding use of only metoclopramide or prucalopride were analyzed following exclusion of reports indicating use for treatment of non-gastrointestinal conditions.

RESULTS

Analysis of 1,085 reports on metoclopramide revealed tardive dyskinesia ( = 393, 36.2%) and dystonia ( = 170, 15.7%) among the most reported ADRs in addition to QTc prolongation ( = 16, 1.5%) with progression to Torsade de pointes ( = 5, 0.5%) and triggering of pheochromocytoma crisis ( = 24, 2.2%). Analysis of 865 reports on prucalopride revealed headache ( = 120, 13.9%), diarrhea ( = 116, 13.4%), and abdominal pain ( = 100, 11.6%) as the most common ADRs with 22 reports (2.5%) of dystonia with the use of prucalopride.

CONCLUSIONS

This FAERS database analysis shows post-marketing reports of ADRs from metoclopramide most frequently include tardive dyskinesia, dystonia, and tremor in addition to potentially fatal arrhythmias such as Torsade de pointes. Consumers of prucalopride may also be at risk of dystonia and other ADRs.